Quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with Huntington's disease

被引:4
|
作者
Sugaya, Keizo [1 ]
Matsubara, Shiro [1 ]
机构
[1] Tokyo Metropolitan Neurol Hosp, Dept Neurol, Fuchu, Tokyo 1830042, Japan
来源
MOLECULAR NEURODEGENERATION | 2012年 / 7卷
关键词
Huntington's disease; Polyglutamine aggregation; SCA3; Stochastic kinetics model; Cumulative damage; One-hit model; Nucleated growth polymerization; Nucleation; Elongation; CAG REPEAT LENGTH; INCLUSION-BODY FORMATION; BASAL GANGLIA VOLUME; ONE-HIT MODEL; AGE-OF-ONSET; PARKINSONS-DISEASE; CLINICAL-FEATURES; MUTANT HUNTINGTIN; OXIDATIVE STRESS; IN-VITRO;
D O I
10.1186/1750-1326-7-20
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Despite enormous progress in elucidating the biophysics of aggregation, no cause-and-effect relationship between protein aggregation and neurodegenerative disease has been unequivocally established. Here, we derived several risk-based stochastic kinetic models that assess genotype/phenotype correlations in patients with Huntington's disease (HD) caused by the expansion of a CAG repeat. Fascinating disease-specific aspects of HD include the polyglutamine (polyQ)-length dependence of both age at symptoms onset and the propensity of the expanded polyQ protein to aggregate. In vitro, aggregation of polyQ peptides follows a simple nucleated growth polymerization pathway. Our models that reflect polyQ aggregation kinetics in a nucleated growth polymerization divided aggregate process into the length-dependent nucleation and the nucleation-dependent elongation. In contrast to the repeat-length dependent variability of age at onset, recent studies have shown that the extent of expansion has only a subtle effect on the rate of disease progression, suggesting possible differences in the mechanisms underlying the neurodegenerative process. Results: Using polyQ-length as an index, these procedures enabled us for the first time to establish a quantitative connection between aggregation kinetics and disease process, including onset and the rate of progression. Although the complexity of disease process in HD, the time course of striatal neurodegeneration can be precisely predicted by the mathematical model in which neurodegeneration occurs by different mechanisms for the initiation and progression of disease processes. Nucleation is sufficient to initiate neuronal loss as a series of random events in time. The stochastic appearance of nucleation in a cell population acts as the constant risk of neuronal cell damage over time, while elongation reduces the risk by nucleation in proportion to the increased extent of the aggregates during disease progression. Conclusions: Our findings suggest that nucleation is a critical step in gaining toxic effects to the cell, and provide a new insight into the relationship between polyQ aggregation and neurodegenerative process in HD.
引用
收藏
页数:20
相关论文
共 50 条
  • [1] Quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with Huntington’s disease
    Keizo Sugaya
    Shiro Matsubara
    Molecular Neurodegeneration, 7
  • [2] Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases
    Truant, Ray
    Atwal, Randy Singh
    Desmond, Carly
    Munsie, Lise
    Tran, Thu
    FEBS JOURNAL, 2008, 275 (17) : 4252 - 4262
  • [3] Poly(trehalose) Nanoparticles Prevent Amyloid Aggregation and Suppress Polyglutamine Aggregation in a Huntington's Disease Model Mouse
    Debnath, Koushik
    Pradhan, Nibedita
    Singh, Brijesh Kumar
    Jana, Nihar R.
    Jana, Nikhil R.
    ACS APPLIED MATERIALS & INTERFACES, 2017, 9 (28) : 24126 - 24139
  • [4] Inhibition of polyglutamine aggregation by SIMILAR huntingtin N-terminal sequences: Prospective molecules for preclinical evaluation in Huntington's disease
    Burra, Gunasekhar
    Thakur, Ashwani Kumar
    BIOPOLYMERS, 2017, 108 (04)
  • [5] Mitochondrial Quality Control in Neurodegenerative Diseases: Focus on Parkinson's Disease and Huntington's Disease
    Franco-Iborra, Sandra
    Vila, Miquel
    Perier, Celine
    FRONTIERS IN NEUROSCIENCE, 2018, 12
  • [6] Biodegradable delivery system containing a peptide inhibitor of polyglutamine aggregation: a step toward therapeutic development in Huntington's disease
    Joshi, Abhayraj S.
    Thakur, Ashwani Kumar
    JOURNAL OF PEPTIDE SCIENCE, 2014, 20 (08) : 630 - 639
  • [7] Molecular Strategies to Target Protein Aggregation in Huntington's Disease
    Jarosinska, Olga D.
    Rudiger, Stefan G. D.
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 8
  • [8] Polyglutamine aggregation in Huntington's disease and spinocerebellar ataxia type 3: similar mechanisms in aggregate formation
    Seidel, K.
    Siswanto, S.
    Fredrich, M.
    Bouzrou, M.
    Brunt, E. R.
    van Leeuwen, F. W.
    Kampinga, H. H.
    Korf, H. -W.
    Rueb, U.
    den Dunnen, W. F. A.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2016, 42 (02) : 153 - 166
  • [9] Polyglutamine Aggregation in Huntington Disease: Does Structure Determine Toxicity?
    Hoffner, Guylaine
    Djian, Philippe
    MOLECULAR NEUROBIOLOGY, 2015, 52 (03) : 1297 - 1314
  • [10] Transgenic Rat Model of Huntington's Disease: A Histopathological Study and Correlations with Neurodegenerative Process in the Brain of HD Patients
    Mazurova, Yvona
    Anderova, Miroslava
    Nemeckova, Ivana
    Bezrouk, Ales
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014